Ying Liang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ying Liang has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
Xieraili Wumener
Department of Nuclear Medicine, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
12 shared publicationsJiuhui Zhao
Department of Nuclear Medicine, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China
9 shared publicationsYarong Zhang
Department of Nuclear Medicine, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College/Shenzhen Clinical Research Center for Cancer, Shenzhen, China
9 shared publicationsFen Du
7 shared publicationsMaoqun Zhang
Department of Nuclear Medicine, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China
6 shared publications- Tao Sun
Paul C. Lauterbur Research Center for Biomedical Imaging, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.
6 shared publications
Latest Publications
- Open Access
- 13 August 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (8) , 1276
A Head-to-Head Comparison of Two Antibodies for HER2 Pretargeted PET Imaging via Bioorthogonal Click Chemistry
Background/Objectives: Antibody selection is critical for advancing pretargeted PET imaging toward clinical translation. This study directly compared two clinically approved anti-HER2 antibodies—trastuzumab and pertuzumab—within an identical pretargeting system, utilizing the specific chemical ligation between tetrazine and trans-cyclooctene (TCO) via the inverse electron-demand Diels–Alder (IEDDA) cycloaddition. Methods: In HER2-positive SKOV3 tumor-bearing mice, TCO-conjugated antibodies were administered 1–13 days prior to injection of a fluorine-18-labeled tetrazine probe ([18F]PEG12-Tz). Results: Both strategies enabled high-contrast imaging, overcoming the kinetic mismatch between slow-clearing antibodies and the short-lived 18F isotope. Distinct profiles were observed: pertuzumab-TCO yielded higher tumor uptake and a broader imaging window (3–13 days), whereas trastuzumab-TCO resulted in lower uptake and a narrower window (1–5 days). These differences are not affinity-driven, as both conjugates showed similar Kd values (~11–14 nM). Instead, pertuzumab-TCO’s superiority stems from a dual mechanism: (1) slower cellular internalization (65.1% vs. 94.0% at 60 min) preserves surface TCO for click reaction; and (2) markedly slower blood clearance (t1/2β = 285.9 h vs. 106.0 h) ensures sustained bioavailability and tumor extravasation. Conclusions: This head-to-head evaluation demonstrates that epitope-dictated internalization and clearance are decisive parameters for antibody selection, providing a mechanism-based framework for optimizing pretargeted imaging.
- 13 August 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (8) , 1276
Open AccessA Head-to-Head Comparison of Two Antibodies for HER2 Pretargeted PET Imaging via Bioorthogonal Click Chemistry
Background/Objectives: Antibody selection is critical for advancing pretargeted PET imaging toward clinical translation. This study directly compared two clinically approved anti-HER2 antibodies—trastuzumab and pertuzumab—within an identical pretargeting system, utilizing the specific chemical ligation between tetrazine and trans-cyclooctene (TCO) via the inverse electron-demand Diels–Alder (IEDDA) cycloaddition. Methods: In HER2-positive SKOV3 tumor-bearing mice, TCO-conjugated antibodies were administered 1–13 days prior to injection of a fluorine-18-labeled tetrazine probe ([18F]PEG12-Tz). Results: Both strategies enabled high-contrast imaging, overcoming the kinetic mismatch between slow-clearing antibodies and the short-lived 18F isotope. Distinct profiles were observed: pertuzumab-TCO yielded higher tumor uptake and a broader imaging window (3–13 days), whereas trastuzumab-TCO resulted in lower uptake and a narrower window (1–5 days). These differences are not affinity-driven, as both conjugates showed similar Kd values (~11–14 nM). Instead, pertuzumab-TCO’s superiority stems from a dual mechanism: (1) slower cellular internalization (65.1% vs. 94.0% at 60 min) preserves surface TCO for click reaction; and (2) markedly slower blood clearance (t1/2β = 285.9 h vs. 106.0 h) ensures sustained bioavailability and tumor extravasation. Conclusions: This head-to-head evaluation demonstrates that epitope-dictated internalization and clearance are decisive parameters for antibody selection, providing a mechanism-based framework for optimizing pretargeted imaging.
- Open Access
- 25 May 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1790374
Synchronous metastatic differentiated high-grade thyroid carcinoma in lymph node from classic papillary thyroid carcinoma: a case report and literature review
Differentiated high-grade thyroid carcinoma (DHGTC) is relatively uncommon. This case report described a 61-year-old male initially diagnosed with classic papillary thyroid carcinoma confined to the thyroid gland, accompanied by skip metastasis to a Level II lymph node. The metastatic lymph node exhibited histopathological progression to DHGTC. Following thyroidectomy for the primary tumor and neck dissection for the metastatic lymph node, the patient received adjuvant radiotherapy to the neck. Subsequently, pathological examination confirmed multiple pulmonary metastases (PMs) from DHGTC within six months of the initial diagnosis. Unfortunately, a post-therapeutic ¹³¹I scan revealed no uptake in the PMs. Genetic testing of the PMs revealed no mutations in BRAF, KRAS, or NRAS, and no RET rearrangement. The patient’s condition was subsequently managed with targeted therapy and immunotherapy, which achieved disease stabilization.
- 25 May 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1790374
Open AccessSynchronous metastatic differentiated high-grade thyroid carcinoma in lymph node from classic papillary thyroid carcinoma: a case report and literature review
Differentiated high-grade thyroid carcinoma (DHGTC) is relatively uncommon. This case report described a 61-year-old male initially diagnosed with classic papillary thyroid carcinoma confined to the thyroid gland, accompanied by skip metastasis to a Level II lymph node. The metastatic lymph node exhibited histopathological progression to DHGTC. Following thyroidectomy for the primary tumor and neck dissection for the metastatic lymph node, the patient received adjuvant radiotherapy to the neck. Subsequently, pathological examination confirmed multiple pulmonary metastases (PMs) from DHGTC within six months of the initial diagnosis. Unfortunately, a post-therapeutic ¹³¹I scan revealed no uptake in the PMs. Genetic testing of the PMs revealed no mutations in BRAF, KRAS, or NRAS, and no RET rearrangement. The patient’s condition was subsequently managed with targeted therapy and immunotherapy, which achieved disease stabilization.
- Open Access
- 21 May 2026
- Published by Springer Nature in EJNMMI Research
- Vol. 16 (1)
From imaging heterogeneity to clinical decision: a novel imaging biomarker based on bone marrow kinetics for advanced NSCLC patients in partial response
Background: Risk of disease progression varies substantially among advanced non-small cell lung cancer (NSCLC) patients who achieve a partial response to initial therapy, and this subgroup currently lacks practical prognostic tools. This study aimed to develop a novel imaging biomarker by assessing bone marrow kinetic heterogeneity via pretreatment dynamic 18 F-fluorodeoxyglucose positron emission tomography/computed tomography ( 18 F-FDG PET/CT). We retrospectively analyzed 51 patients with advanced NSCLC, focusing on the 32 who attained a partial response following first-line treatment. Time-activity curves (TACs) from the tumor and bone marrow were metabolically decomposed. Through integrated analysis of clinical characteristics, conventional PET parameters, and 28 TAC-derived features, coupled with a rigorous bootstrap-LASSO-Cox procedure (1000 resamples) for robust feature selection, we developed a multivariate Cox model and a simplified risk-stratification model. Results: The bootstrap-LASSO-Cox analysis identified the slope of the bone marrow free FDG TAC between 10 and 30 min post-injection (BM_C f _Slope 10−30 ) as the most significant independent predictor. In the multivariate Cox model, this feature was strongly associated with a reduced risk of progression (Hazard Ratio = 0.10, 95% CI: 0.03–0.35, P < 0.001) and demonstrated good discriminative ability (C-index = 0.77, 95% CI: 0.68–0.86). Using an optimal cutoff value of -0.01119, this single parameter significantly stratified patients into high- and low-risk groups with distinct progression-free survival (Log-rank P < 0.001). The simplified model showed robust predictive performance, with average time-dependent AUCs of 0.792, 0.774, and 0.731 at 12, 18, and 24 months, respectively, and provided clinical net benefit. Neither conventional metabolic parameters nor clinical characteristics showed significant predictive value. Conclusion: For advanced NSCLC patients achieving an initial partial response, pretreatment assessment of bone marrow kinetics via dynamic 18 F-FDG PET/CT emerges as a potential prognostic biomarker. The TAC slope feature, which reflects early interstitial clearance, can identify patients at high risk of early progression, offering potential for personalizing surveillance strategies and guiding timely therapeutic interventions.
- 21 May 2026
- Published by Springer Nature in EJNMMI Research
- Vol. 16 (1)
Open AccessFrom imaging heterogeneity to clinical decision: a novel imaging biomarker based on bone marrow kinetics for advanced NSCLC patients in partial response
Background: Risk of disease progression varies substantially among advanced non-small cell lung cancer (NSCLC) patients who achieve a partial response to initial therapy, and this subgroup currently lacks practical prognostic tools. This study aimed to develop a novel imaging biomarker by assessing bone marrow kinetic heterogeneity via pretreatment dynamic 18 F-fluorodeoxyglucose positron emission tomography/computed tomography ( 18 F-FDG PET/CT). We retrospectively analyzed 51 patients with advanced NSCLC, focusing on the 32 who attained a partial response following first-line treatment. Time-activity curves (TACs) from the tumor and bone marrow were metabolically decomposed. Through integrated analysis of clinical characteristics, conventional PET parameters, and 28 TAC-derived features, coupled with a rigorous bootstrap-LASSO-Cox procedure (1000 resamples) for robust feature selection, we developed a multivariate Cox model and a simplified risk-stratification model. Results: The bootstrap-LASSO-Cox analysis identified the slope of the bone marrow free FDG TAC between 10 and 30 min post-injection (BM_C f _Slope 10−30 ) as the most significant independent predictor. In the multivariate Cox model, this feature was strongly associated with a reduced risk of progression (Hazard Ratio = 0.10, 95% CI: 0.03–0.35, P < 0.001) and demonstrated good discriminative ability (C-index = 0.77, 95% CI: 0.68–0.86). Using an optimal cutoff value of -0.01119, this single parameter significantly stratified patients into high- and low-risk groups with distinct progression-free survival (Log-rank P < 0.001). The simplified model showed robust predictive performance, with average time-dependent AUCs of 0.792, 0.774, and 0.731 at 12, 18, and 24 months, respectively, and provided clinical net benefit. Neither conventional metabolic parameters nor clinical characteristics showed significant predictive value. Conclusion: For advanced NSCLC patients achieving an initial partial response, pretreatment assessment of bone marrow kinetics via dynamic 18 F-FDG PET/CT emerges as a potential prognostic biomarker. The TAC slope feature, which reflects early interstitial clearance, can identify patients at high risk of early progression, offering potential for personalizing surveillance strategies and guiding timely therapeutic interventions.
- Open Access
- 1 March 2026
- Published by AME Publishing Company in Quantitative Imaging in Medicine and Surgery
- Vol. 16 (3) , 249
Dynamic fluorine-18 fluorodeoxyglucose PET for evaluating different-sized metastatic lymph nodes in patients with non-small cell lung cancers
Background: For patients with non-small cell lung cancer (NSCLC), accurate and detailed lymph node (LN) staging is crucial for treatment planning and prognosis. However, reliably distinguishing metastatic from nonmetastatic LNs remains a clinical challenge, especially in small-sized LNs. A retrospective study was conducted to evaluate the ability of dynamic fluorine-18 fluorodeoxyglucose (F-18 FDG) positron emission tomography (PET), specifically the metabolic parameter of net influx rate (Ki), in distinguishing metastatic from and nonmetastatic LNs of different sizes in patients with NSCLC. Methods: In the study, 366 patients with lung nodules or masses detected on chest computed tomography (CT) scan underwent dynamic chest F-18 FDG PET/CT and static whole-body F-18 FDG PET/CT imaging after providing informed consent. A retrospective collection of 369 LNs in 98 patients with NSCLC was pathologically confirmed. CT features [density, maximum short diameter (Dmax), ratio of LN long diameter to short diameter (L/S), and ratio of LN density to muscle density (DR)] and static PET features [maximum standardized uptake value (SUVmax) and ratio of LN SUVmax to mediastinal blood pool SUVmax (SUVR)] of the LNs were measured. The Ki was also obtained through the application of an irreversible two-tissue compartment model. CT features, PET features, and Ki were compared between the metastatic and nonmetastatic LNs via the Wilcoxon rank-sum test. Receiver operating characteristic (ROC) analysis was performed for each parameter. Differences in area under the curve (AUC) were assessed via the DeLong test. Differences in sensitivity and specificity at a given threshold were compared using χ2 test. PResults: Among the 369 LNs, 172 were metastatic, and 197 were nonmetastatic. The CT features, static PET features, and Ki were significantly different between the metastatic and nonmetastatic LNs (Pmax, SUVmax, SUVR, and Ki were 0.852, 0.894, 0.888, and 0.936, respectively, while those of other features were max, 7.65 for SUVmax, 4.54 for SUVR, and 0.018 mL/g/min for Ki. The Delong test was carried out on the features with an AUC above 0.8 and showed that Ki had a higher diagnostic efficacy compared to the other features (Pmax ≥1 cm and Dmax max max ≥ 1 cm group. Conclusions: Compared with static PET features and CT features, the dynamic PET parameter Ki demonstrated superior diagnostic performance in differentiating metastatic from nonmetastatic LNs, particularly in the group of small LNs. After optimization of the cutoff value, the Ki improved the clinical applicability in identifying metastatic LNs.
- 1 March 2026
- Published by AME Publishing Company in Quantitative Imaging in Medicine and Surgery
- Vol. 16 (3) , 249
Open AccessDynamic fluorine-18 fluorodeoxyglucose PET for evaluating different-sized metastatic lymph nodes in patients with non-small cell lung cancers
Background: For patients with non-small cell lung cancer (NSCLC), accurate and detailed lymph node (LN) staging is crucial for treatment planning and prognosis. However, reliably distinguishing metastatic from nonmetastatic LNs remains a clinical challenge, especially in small-sized LNs. A retrospective study was conducted to evaluate the ability of dynamic fluorine-18 fluorodeoxyglucose (F-18 FDG) positron emission tomography (PET), specifically the metabolic parameter of net influx rate (Ki), in distinguishing metastatic from and nonmetastatic LNs of different sizes in patients with NSCLC. Methods: In the study, 366 patients with lung nodules or masses detected on chest computed tomography (CT) scan underwent dynamic chest F-18 FDG PET/CT and static whole-body F-18 FDG PET/CT imaging after providing informed consent. A retrospective collection of 369 LNs in 98 patients with NSCLC was pathologically confirmed. CT features [density, maximum short diameter (Dmax), ratio of LN long diameter to short diameter (L/S), and ratio of LN density to muscle density (DR)] and static PET features [maximum standardized uptake value (SUVmax) and ratio of LN SUVmax to mediastinal blood pool SUVmax (SUVR)] of the LNs were measured. The Ki was also obtained through the application of an irreversible two-tissue compartment model. CT features, PET features, and Ki were compared between the metastatic and nonmetastatic LNs via the Wilcoxon rank-sum test. Receiver operating characteristic (ROC) analysis was performed for each parameter. Differences in area under the curve (AUC) were assessed via the DeLong test. Differences in sensitivity and specificity at a given threshold were compared using χ2 test. PResults: Among the 369 LNs, 172 were metastatic, and 197 were nonmetastatic. The CT features, static PET features, and Ki were significantly different between the metastatic and nonmetastatic LNs (Pmax, SUVmax, SUVR, and Ki were 0.852, 0.894, 0.888, and 0.936, respectively, while those of other features were max, 7.65 for SUVmax, 4.54 for SUVR, and 0.018 mL/g/min for Ki. The Delong test was carried out on the features with an AUC above 0.8 and showed that Ki had a higher diagnostic efficacy compared to the other features (Pmax ≥1 cm and Dmax max max ≥ 1 cm group. Conclusions: Compared with static PET features and CT features, the dynamic PET parameter Ki demonstrated superior diagnostic performance in differentiating metastatic from nonmetastatic LNs, particularly in the group of small LNs. After optimization of the cutoff value, the Ki improved the clinical applicability in identifying metastatic LNs.
- Open Access
- 13 February 2026
- Published by Springer Nature in EJNMMI Research
- Vol. 16 (1)
Multi-view deep learning for automated lymphoma staging from 18F-FDG PET/CT: physician-level accuracy with high-throughput workflow
Lymphoma staging plays a pivotal role in guiding risk-adapted therapeutic strategies. While the Ann Arbor system is the standard for staging lymphoma, curr
- 13 February 2026
- Published by Springer Nature in EJNMMI Research
- Vol. 16 (1)
Open AccessMulti-view deep learning for automated lymphoma staging from 18F-FDG PET/CT: physician-level accuracy with high-throughput workflow
Lymphoma staging plays a pivotal role in guiding risk-adapted therapeutic strategies. While the Ann Arbor system is the standard for staging lymphoma, curr
- Open Access
- 12 February 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1752947
The value of metabolic parameters on dynamic 18F-FDG PET/CT for predicting lymph node metastasis in non-small cell lung cancer
Objectives: To evaluate the predictive value of dynamic 18 F-FDG PET/CT metabolic parameters of the primary tumor for mediastinal lymph node metastasis (LNM) in non-small cell lung cancer (NSCLC). Methods: A total of 316 patients with clinically suspected but untreated lung lesions who underwent dynamic PET/CT and static PET/CT scans from May 2021 to November 2024 were retrospectively collected in this study. Quantitative parameters including K1, k2, k3, and Ki of each lesion, were obtained by applying the irreversible two-tissue compartmental modeling using an in-house Matlab software. Time-activity curves (TACs) at the primary tumor were extracted from each dynamic 18 F-FDG PET/CT scan. The TAC signal was then decomposed into metabolism and blood flow components through kinetic modeling. Dynamic features including area under the curve (AUC), time-to-peak (t peak ), and slopes were then extracted from each component. Predictive analyses were performed using multivariate logistic regression to determine the predictive factors for LNM. Receiver-operating characteristic (ROC) analysis was performed to evaluate the predictive performance of models. Results: One hundred and fifteen patients who obtained LN biopsy within one month were enrolled in this study. Based on the results of the pathology, the patients were divided into LNM and non-LNM groups. The multivariate logistic regression analyses showed that the TLG, slope 10-30min , and CA125 were independent predictive factors for LNM ( P < 0.05, respectively). For the model comparison, composite model achieved the highest diagnostic efficacy (AUC of 0.867, sensitivity 75.5%, specificity 84.5%, accuracy 80.2%) compared with PET/CT model (AUC of 0.822, sensitivity 80.0%, specificity 72.4%, accuracy 75.7%) and clinical model (AUC of 0.792, sensitivity 49.1%, specificity 96.7%, accuracy 73.9%). Conclusion: The metabolic parameters based on dynamic and static 18 F-FDG PET/CT combined with CA125 can improve N-staging accuracy in patients with NSCLC.
- 12 February 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1752947
Open AccessThe value of metabolic parameters on dynamic 18F-FDG PET/CT for predicting lymph node metastasis in non-small cell lung cancer
Objectives: To evaluate the predictive value of dynamic 18 F-FDG PET/CT metabolic parameters of the primary tumor for mediastinal lymph node metastasis (LNM) in non-small cell lung cancer (NSCLC). Methods: A total of 316 patients with clinically suspected but untreated lung lesions who underwent dynamic PET/CT and static PET/CT scans from May 2021 to November 2024 were retrospectively collected in this study. Quantitative parameters including K1, k2, k3, and Ki of each lesion, were obtained by applying the irreversible two-tissue compartmental modeling using an in-house Matlab software. Time-activity curves (TACs) at the primary tumor were extracted from each dynamic 18 F-FDG PET/CT scan. The TAC signal was then decomposed into metabolism and blood flow components through kinetic modeling. Dynamic features including area under the curve (AUC), time-to-peak (t peak ), and slopes were then extracted from each component. Predictive analyses were performed using multivariate logistic regression to determine the predictive factors for LNM. Receiver-operating characteristic (ROC) analysis was performed to evaluate the predictive performance of models. Results: One hundred and fifteen patients who obtained LN biopsy within one month were enrolled in this study. Based on the results of the pathology, the patients were divided into LNM and non-LNM groups. The multivariate logistic regression analyses showed that the TLG, slope 10-30min , and CA125 were independent predictive factors for LNM ( P < 0.05, respectively). For the model comparison, composite model achieved the highest diagnostic efficacy (AUC of 0.867, sensitivity 75.5%, specificity 84.5%, accuracy 80.2%) compared with PET/CT model (AUC of 0.822, sensitivity 80.0%, specificity 72.4%, accuracy 75.7%) and clinical model (AUC of 0.792, sensitivity 49.1%, specificity 96.7%, accuracy 73.9%). Conclusion: The metabolic parameters based on dynamic and static 18 F-FDG PET/CT combined with CA125 can improve N-staging accuracy in patients with NSCLC.
- Open Access
- 8 December 2025
- Published by Springer Nature in EJNMMI Physics
- Vol. 12 (1)
Neural network-aided unsupervised input function estimation for dual-time-window PET Patlak analysis
This study aims to develop and validate a dual-time-window (DTW) Patlak plot method that eliminates the need for invasive blood sampling and reduces scan d
- 8 December 2025
- Published by Springer Nature in EJNMMI Physics
- Vol. 12 (1)
Open AccessNeural network-aided unsupervised input function estimation for dual-time-window PET Patlak analysis
This study aims to develop and validate a dual-time-window (DTW) Patlak plot method that eliminates the need for invasive blood sampling and reduces scan d
- Open Access
- 22 September 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1637366
Predictive value of radiomics modeling based on dynamic and static 18F-FDG PET/CT imaging for the differential diagnosis of lymph nodes in lung cancer
Background: We aimed to identify the most effective machine learning model for predicting the differential diagnosis of lymph nodes (LNs) in lung cancer using dynamic and static 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) imaging.Methods: A total of 279 pathologically confirmed LNs from 74 patients with lung cancer were retrospectively analyzed. These were randomly divided into a training group (n = 196) and a test group (n = 83) at a ratio of 7:3. The radiomics features of the images were extracted from CT, dynamic PET (dPET), and static PET (sPET) images and were screened for the most predictive value. Support vector machine (SVM), logistic regression (LR), and random forest (RF) machine learning models were built using the optimal radiomics features. The best quantitative prediction model was suggested using SUVmax and Ki based on LNs. A composite model was built combining the best machine learning model and the quantitative model. Receiver operating characteristic (ROC) curves were used to evaluate the predictive ability of the machine learning, quantitative, and composite models for LN metastasis in lung cancer.Results: Of the three machine learning models, the RF model demonstrated the greatest predictive efficacy in both the training [area under the curve (AUC) = 0.823] and test groups (AUC = 0.819). The quantitative model based on Ki showed good predictive efficacy in both the training (AUC = 0.772) and test groups (AUC = 0.805). A composite model based on both the RF machine learning model and the quantitative model demonstrated superior predictive efficacy. The AUCs in the training and test groups were 0.844 and 0.835, respectively. Decision curve analysis showed that the composite model had better net benefit and clinical value.Conclusion: A composite model based on an RF model of PET/CT+Ki images combined with dynamic quantitative Ki is highly effective in differentiating FDG-avid LN metastasis in lung cancer. This model provides greater net benefit and clinical value.
- 22 September 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1637366
Open AccessPredictive value of radiomics modeling based on dynamic and static 18F-FDG PET/CT imaging for the differential diagnosis of lymph nodes in lung cancer
Background: We aimed to identify the most effective machine learning model for predicting the differential diagnosis of lymph nodes (LNs) in lung cancer using dynamic and static 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) imaging.Methods: A total of 279 pathologically confirmed LNs from 74 patients with lung cancer were retrospectively analyzed. These were randomly divided into a training group (n = 196) and a test group (n = 83) at a ratio of 7:3. The radiomics features of the images were extracted from CT, dynamic PET (dPET), and static PET (sPET) images and were screened for the most predictive value. Support vector machine (SVM), logistic regression (LR), and random forest (RF) machine learning models were built using the optimal radiomics features. The best quantitative prediction model was suggested using SUVmax and Ki based on LNs. A composite model was built combining the best machine learning model and the quantitative model. Receiver operating characteristic (ROC) curves were used to evaluate the predictive ability of the machine learning, quantitative, and composite models for LN metastasis in lung cancer.Results: Of the three machine learning models, the RF model demonstrated the greatest predictive efficacy in both the training [area under the curve (AUC) = 0.823] and test groups (AUC = 0.819). The quantitative model based on Ki showed good predictive efficacy in both the training (AUC = 0.772) and test groups (AUC = 0.805). A composite model based on both the RF machine learning model and the quantitative model demonstrated superior predictive efficacy. The AUCs in the training and test groups were 0.844 and 0.835, respectively. Decision curve analysis showed that the composite model had better net benefit and clinical value.Conclusion: A composite model based on an RF model of PET/CT+Ki images combined with dynamic quantitative Ki is highly effective in differentiating FDG-avid LN metastasis in lung cancer. This model provides greater net benefit and clinical value.
- Open Access
- 10 September 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1663104
Case Report: NUTM1-rearranged lung sarcoma: a rare case imaged with dynamic and static 18F-FDG PET/CT
Background: Nuclear protein of testis midline carcinoma family member 1 (NUTM1)-rearranged lung sarcomas are rare malignant malignancies. 18F-fluorodeoxyglucose (FDG) positron emission tomography/CT (PET/CT) is widely used for the differential diagnosis and staging of malignant tumours. This study aimed to identify the static and dynamic features of 18F-FDG PET/CT in NUTM1-rearranged lung sarcomas.Case Description: A 46-year-old male patient underwent a chest CT scan for trauma, which revealed a tumor in the hilum of the left lung. The patient also underwent dynamic (chest) and static (whole body) PET/CT scans. The dynamic and static 18F-FDG PET/CT scans showed a tumor in the hilum of the left lung, with a size of 8.6×6.7 cm, an SUVmax of 17.6 and a Ki of 0.0668 ml/g/min. Final pathology and genetic testing confirmed NUTM1-rearranged lung sarcoma.Conclusions: This case shows dynamic and static 18F-FDG PET/CT and pathological features of NUTM1-rearranged lung sarcomas.
- 10 September 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1663104
Open AccessCase Report: NUTM1-rearranged lung sarcoma: a rare case imaged with dynamic and static 18F-FDG PET/CT
Background: Nuclear protein of testis midline carcinoma family member 1 (NUTM1)-rearranged lung sarcomas are rare malignant malignancies. 18F-fluorodeoxyglucose (FDG) positron emission tomography/CT (PET/CT) is widely used for the differential diagnosis and staging of malignant tumours. This study aimed to identify the static and dynamic features of 18F-FDG PET/CT in NUTM1-rearranged lung sarcomas.Case Description: A 46-year-old male patient underwent a chest CT scan for trauma, which revealed a tumor in the hilum of the left lung. The patient also underwent dynamic (chest) and static (whole body) PET/CT scans. The dynamic and static 18F-FDG PET/CT scans showed a tumor in the hilum of the left lung, with a size of 8.6×6.7 cm, an SUVmax of 17.6 and a Ki of 0.0668 ml/g/min. Final pathology and genetic testing confirmed NUTM1-rearranged lung sarcoma.Conclusions: This case shows dynamic and static 18F-FDG PET/CT and pathological features of NUTM1-rearranged lung sarcomas.